Introduction

TAL1/SCL (hereafter referred to as TAL1) is a basic helix-loop-helix (bHLH) transcription factor
that is required for normal hematopoiesis 1, 2 , and whose aberrant expression leads to T-cell acute lymphoblastic leukemia (T-ALL). TAL1 is expressed by the leukemic cells of 60% of T-ALL patients 3, 4 as a result of chromosomal translocations or intrachromosomal rearrangements leading to its monoallelic expression, as well as by unknown mechanisms leading to biallelic upregulation in double-positive thymocytes 5, 6 . According to the prevailing model of TAL1-induced leukemogenesis, TAL1 acts as a transcriptional repressor through heterodimerization with E2A
and HEB, leading to a block of the transcriptional activity of these class-I bHLH factors [7] [8] [9] [10] [11] [12] .
However, transcriptional activation of the RALDH2 gene by TAL1 has also been described suggesting a more complex effect on gene regulation 13 . Despite the importance of transcriptional programs downstream of TAL1, the collection of genes directly regulated by TAL1 is mostly unknown. Although TAL1 targets have been reported in the context of early hematopoietic development (KIT) 14 , red cell differentiation (GPA and P4.2) 15, 16 , T-cell development (pTA is a likely target of TAL1) [17] [18] [19] or leukemia (RALDH2) 13 , none of them has elucidated the regulatory roles that TAL1 plays in the pathogenesis of T-ALL. The identification of a more comprehensive set of genes regulated by TAL1 will lead to improved understanding of the transcriptional role of TAL1 and its regulation circuits that control cell proliferation, differentiation and apoptosis during Tcell development.
Here, we elucidated the regulatory circuitry regulated by TAL1 in T-ALL using a combination of complementary genome-scale analysis techniques. To identify regions in the genome directly occupied by TAL1 in vivo, we combined chromatin immunoprecipitation and custom-made promoter microarrays (ChIP-chip) [20] [21] [22] [23] [24] . This analysis was combined with TAL1 knockdown by RNA interference (RNAi) and gene expression profiling in primary samples using oligonucleotide microarrays to analyze the mechanisms of TAL1 transformation on a genome-wide scale. Our results support that TAL1 may function both as repressor and as activator of direct target genes whose promoters are also bound by E2A and HEB. We also demonstrate that several of the genes whose promoters are occupied by TAL1 in a T-ALL cell line are also specifically associated with the expression of this transcription factor in human primary leukemias. Our results suggest that transcriptional effects downstream of the aberrant expression of TAL1 in T-cell progenitors are amplified in a complex transcriptional network that results in the disruption of critical mechanisms that control cell homeostasis during thymocyte development.
only.
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Materials and Methods
Human Cell Lines
The T-ALL Jurkat cell line clone E6-1 was obtained from the American Type Culture Collection (ATCC) and was grown in RPMI media with 10% Fetal Bovine Serum (FBS) in a humidified 5% CO2 atmosphere at 37 °C. EBNA packaging cell line was obtained from the ATCC. EBNA cells were grown in DMEM media with 10% FBS in 5% CO2 at 37°C.
RNAi Constructs
An RNAi control sequence was obtained from Qiagen. The RNAi sequence against TAL1 (nt 879-897) was described in Lazrak et al., 2004 25 . Both sequences were cloned into the BglII/HindIII sites of the pSuperior (Oligoengine) retroviral vector.
Generation of Retrovirus
Recombinant retroviruses were produced using the EBNA packaging cell line that was transfected with the pSuperior construct containing the control RNAi sequence or sequence directed against TAL1 along with plasmids encoding the gagpol and VSVg genes. The viral supernatant was collected 48 hours after transfection and filtered through a 0.45 μM filter.
Generation of Jurkat Cell Clones with RNAi-induced TAL1 Knockdown
Jurkat cells (3 x 10 6 cells) were infected with 2 ml of viral supernatant in the presence of 9 μg/ml polybrene. Forty-eight hours after infection, the cells were selected in media containing 1μg/ml puromycin. Oligoclonal cell lines were generated by plating 5 cells/well in 96-well plates. The level of TAL1 knockdown was assessed by Western Blot using a mouse monoclonal TAL1-specific antibody BTL73 generously provided by Dr. K. Pulford, Oxford University, UK 26 . To ensure equal loading, the blot was stripped and reprobed with an antibody specific for α-tubulin (Sigma).
Total RNA Preparation and Real-Time PCR Analysis
Total RNA was extracted using the RNAqueousTM kit (Ambion) following the manufacturer's instructions. cDNA was generated using 2 μg of RNA and the ThermoScript TM RT-PCR System (Invitrogen). The cDNA was then analyzed by quantitative PCR using the Sybr Green RT-PCR Core Reagents kit (Applied Biosystems). The primer sequences of the oligonucleotides used for RT-PCR are available upon request.
Growth and Apoptosis Assays
Cell growth ratios were determined by a colorimetric assay using the Cell Proliferation Kit I (MTT) (Roche). Briefly, triplicate samples corresponding to two clones expressing the control shRNA and two clones expressing TAL1 shRNA were plated at a density of 5x10 4 cells/ml. Samples were taken every day and tested using the MTT assay following the manufacturer's protocol. Apoptosis was quantified using the Annexin V: FITC Apoptosis Detection Kit I (BD-Pharmingen) following the only.
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Chromatin Immunoprecipitation Reagents
TAL1#370 antibodies were generously provided by Dr Richard Baer from Columbia University.
Typical chromatin immunoprecipitation (ChIP) reactions used 50 µl of antisera per experiment, in combination with 100 µL of a protein G magnetic bead suspension obtained from Dynal (Norway).
Antiserum#370 was raised against GST-TAL1 (238-331), a fusion protein containing the carboxyterminal 94 residues of TAL1 9 , and it recognizes both p42 TAL1 and p22 forms of TAL1 27 . E2A was immunoprecipitated for most of the experiments reported here using a rabbit polyclonal antibody 28 and verified using a monoclonal antibody G98-271 (BD Biosciences-Pharmingen) against human E2A that recognizes specifically human E12 and E47, the two alternative spliced products of the E2A gene. HEB was immunoprecipitated using Santa Cruz Ab sc-357. 10 μg of antibody were used per chromatin immunoprecipitation.
ChIP on chip
Complete protocols are available for download in pdf format at http://web.wi.mit.edu/young/TAL1. 
ChIP Hybridization Quality Control
The raw data generated from each array experiment was subjected to multiple levels of quality control. First, each scan was examined visually as it was being performed. Samples on microarrays with gross defects (e.g. scratches, smeared spots) were repeated. We also determined that no reliable signal was produced from control spots containing Arabidopsis DNA. 
Binding Site Determination and Error Model
Scanned images were analyzed using GenePix (v3.1 or v4.0), to obtain background-subtracted intensity values. Each spot is hybridized by both IP-enriched and unenriched DNA, which are labeled with different fluorophores. Consequently, each spot yields fluorescence intensity information in two channels, corresponding to immunoprecipitated DNA and genomic DNA. To account for background hybridization to slides, the median intensity of a set of control blank spots was subtracted for site-specific transcription factors (TAL1). To correct for different amounts of genomic and immunoprecipitated DNA hybridized to the microarray, the median intensity value of the IP-enriched DNA channel was divided by the median of the genomic DNA channel, and this normalization factor was applied to each intensity in the genomic DNA channel. Next, we calculated the log of the ratio of intensity in the IP-enriched channel to intensity in the genomic DNA channel for each intergenic region across the entire set of hybridization experiments.
Adjusted intensity values for the IP-enriched channel were calculated from these ratios. A wholechip error model 29, 30 was then used to calculate confidence values for each spot on each microarray, and to combine data for the replicates of each experiment to obtain a final average ratio and confidence for each promoter region. Raw promoter array scanning data as well as more detailed information about data interpretation models can be found at http://web.mit.wi.mit.edu/young/TAL1.
Gene expression profiling in primary T-ALL samples
Microarray analysis of 45 primary leukemia specimens was performed on diagnostic lymphoblast samples obtained from the POG tumor bank. All samples were obtained with informed consent and were analyzed under the supervision of the University of New Mexico IRB. Gene expression profiling using oligonucleotide microarrays was performed using Affymetrix U133 arrays following standard procedures and interarray intensity differences were normalized with Dchip. Quantitative
RT-PCR analysis on T-ALL major oncogenes including HOX11, HOX11L2, TAL1, LYL1, TAL2 and
BHLHB1 was performed as previously described 3 . Nearest-neighbor analysis of genes associated with the expression of TAL1 was performed with Genecluster 2.0.
Results
Identification of TAL1 bound promoters by ChIP on chip
To identify direct target genes regulated by TAL1 in T-ALL, we performed ChIP on chip in Jurkat cells using a polyclonal antibody that recognizes multiple TAL1 isoforms and a custom genomic microarray containing 5' proximal promoter regions of 13,000 human genes (Hu13K array) 21 . For this manuscript, the term of direct target includes all promoters that are bound by TAL1, either by direct interaction with the DNA 15 or indirectly as a member of a DNA-binding complex, as TAL1
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The experiment was performed in triplicate and analyzed to identify promoters that are significantly bound in vivo by TAL1, ( Figure 1A and Figure S1 ). We identified 71 genes whose promoters showed significant binding of TAL1 compared to the chromatin control (p<0.001 in triplicate experiments). Classification of these TAL1 direct target genes according to Gene-Ontology categories showed that they belong to multiple functional groups (Figure 1b array. Indeed, TAL1 binds to RALDH2 an intronic sequence 13 , while the binding to CD4 occurs in upstream enhancer regions 8 , both not present on the Hu13K promoter array (Table S1) We confirmed the ChIP-chip results by performing chromatin immunoprecipitation coupled to quantitative PCR for each of the 71 promoters bound on the arrays. Our results verified the binding of TAL1 to 57/71 promoters (80% of the identified targets) (Figure 2 ), which is in agreement with validation rates previously reported for ChIP on chip results using similar platforms 21 .
Further analysis of the promoters with TAL1 binding by ChIP on chip indicated that ~95% (64/71) contained E-boxes and that ~85% (60/71) contained GATA boxes in the proximal promoter sequence. When analyzed specifically for CAGATG, which is the previously described E-box motif preferred by TAL1, 24% of the TAL1 targets (17/71) contained this sequence in their promoters.
There is a weak enrichment (1.14 fold change) for the CATATG motif in the TAL1 targets compared to all the promoters on the entire Hu13K array, although this does not represent a significant enrichment (one-tailed binomial test p-value of 0.318). None of the TAL1 occupied promoters showed a prototypical E-box-GATA motif described by Wadman and colleagues as This result strongly suggests that at least a fraction of the targets identified by TAL1 in Jurkat cells are likely to be regulated in a broader spectrum of T-cell leukemias.
For
TAL1 binds to its target promoters in the presence of E2A and HEB
TAL1 is a class II bHLH factor that requires heterodimerization with class I bHLH members such as E2A (E12/E47) and HEB, to achieve efficient interaction with E-box (CANNTG) DNA sequences situated in the promoter regions of its target genes 32 . To further extend the ChIP on chip results, we analyzed the promoter occupancy of E2A and HEB in this set of TAL1 direct targets in Jurkat T-ALL cells. E2-2, another member of the E-protein family of transcription factors that had been previously described as to interact with TAL1 33 , was not expressed at significant levels in Western blot analysis of Jurkat cells (data not shown) and therefore was not tested by chIP. Chromatin immunoprecipitation using antibodies that recognize both alternative splice forms of E2A (E12 and For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From knockdown resulted in the regulation of only a fraction of the genes identified by ChIP on chip (16%). Specifically TAL1 downregulation results in a reduction in the transcription of 3 genes (TRAF3, RAB40B and EPHB1) and an increase in transcription of 3 (PTPRU, TTC3 and RPS3A) using a Satterthwaite t-test at a significance level p<0.05 (Figure 4) , indicating a role of TAL1 as a transcriptional activator for TRAF3, RAB40B and EPHB1 and as a repressor of PTPRU, TTC3 and RPS3A respectively. There was no significant effect on the expression levels of the remaining 30 TAL1 direct target genes under our experimental conditions. Even though we achieved a 70-80% level of TAL1 knockdown, TAL1 is a very highly expressed protein in Jurkat cells, and we cannot exclude the possibility that the remaining TAL1 protein after RNA interference would still be enough to modulate the transcription of some TAL1 target genes in the knockdown cells. It is also possible that many of these targets are not functional in the cell lines we are profiling, yet are active in other tissue types. This is consistent with similar correlations between promoter binding and gene regulation for c-Jun/ATF2, CREB and the glucocorticoid receptor addressed in several recent publications demonstrating that promoter occupancy by these regulatory proteins influences 2-35 % of gene expression 34, 35, 36, 37 . These findings suggest that although transcription factors may bind to multiple target genes in a given cell type, transcriptional regulation may occur only in those genes whose promoters are simultaneously occupied by a relevant set of tissue specific transcriptional coregulators.
Expression of TAL1 direct targets in primary samples from human T-ALL patients
To analyze the association of TAL1 targets identified by ChIP on chip with the aberrant expression Combined analysis of ChIP-on-chip data and gene expression profiling was used to search for additional genes within the TAL1 direct targets that are associated with the TAL1 positive leukemias. Using a t-test nearest neighbor analysis that calculates a combined p-value including the combined significance of the expression data and the ChIP on chip results, we selected 8 TAL1 direct target genes with a combined p value <0.1 ( Table 1) . Two of these genes -RPS3A
and PTPRU -had been analyzed by RT-PCR after TAL1 knockdown by RNA interference and had been found to be repressed by TAL1 (Figure 4 Figure   5B ). Importantly three of these genes (IL10RA, FRG1 and SERPINB2) showed higher levels of expression in TAL1-positive samples, suggesting that TAL1 may activate their expression, while only one (TTC3) showed lower levels of expression in the TAL1 group, and thus is presumably repressed by TAL1 ( Figure 5B ).
Discussion
We have analyzed the transcriptional effects of TAL1 expression in the context of human T-cell acute leukemia, using TAL1 ChIP-chip analysis coupled with RNA interference to knockdown TAL1 expression. The combined analysis of ChIP-chip data and gene expression profiling in T-ALL samples demonstrates that some of the genes we have identified by ChIP on chip in the Jurkat cell line are also regulated in the primary human leukemias that over express TAL1.
Using ChIP-chip we have identified 71 direct target genes of TAL1 in T-ALL and verified the binding of the transcription factor to 80% of them. Analysis of the promoters bound by TAL1 identified by ChIP-chip indicates that TAL1 frequently binds to its direct target genes as part of regulatory complexes that also contain the class I bHLH factors E2A or HEB. However, in contrast with current models that generally support a role for TAL1 as a transcriptional repressor by interfering with the transcriptional regulation elicited by the tumor suppressor E2A 11, 8, 12, 18, 19, 38, 39 , our results suggest that TAL1 inactivation by RNAi results in both activation and repression of multiple direct target genes, in agreement with a more complex transcriptional regulatory role for TAL1 in T-ALL cells. Many of the genes whose promoters are occupied by TAL1 do not seem to be affected by TAL1 downregulation by RNA interference. Possibly, the level of TAL1 knockdown only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From in our clones is not enough to alter the transcription rates of these promoters, as the knockdown cells still express some TAL1 protein, which may be sufficient to allow basal levels of transcription of specific TAL1 targets. However, an effect on cell growth was observed with the levels of TAL1 knockdown that could be attained, suggesting that a subset of critical TAL1direct target genes should be measurably regulated. Aberrant expression of TAL1 in T-ALL lymphoblasts results in 
